Hreinn Benonisson
Leiden, ZH 2333ZA, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Restoring tumor immunogenicity with dendritic cell reprogramming.
Journal: Science immunology
Published: July 07, 2023
Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice.
Journal: Cancers
Published: February 24, 2021
Immunogenicity of rat-neu+ mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment.
Journal: Scientific reports
Published: September 29, 2019
CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory.
Journal: Molecular cancer therapeutics
Published: June 20, 2018
High FcγR Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: May 17, 2018
FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.
Journal: International journal of cancer
Published: March 30, 2018
A Restricted Role for FcγR in the Regulation of Adaptive Immunity.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: March 24, 2017
Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness.
Journal: PloS one
Published: November 09, 2012
The adjuvant LT-K63 can restore delayed maturation of follicular dendritic cells and poor persistence of both protein- and polysaccharide-specific antibody-secreting cells in neonatal mice.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: July 04, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026